Terconazole is an antifungal prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of vulvovaginal candidiasis, which is an infection of the female vulva and vagina and is a type of mucocutaneous candidiasis.
Mucocutaneous candidiasis is a fungal infection that is caused by Candida yeasts and affects the skin and mucous membranes (such as in the mouth or vagina). Mucocutaneous candidiasis (also called mucosal candidiasis) is an opportunistic infection. An opportunistic infection is an infection that occurs more frequently or is more severe in people with weakened immune systems—such as those infected with HIV—than in people with healthy immune systems.
The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association of the Infectious Diseases Society of America (IDSA-HIVMA), includes recommendations on the HIV-related use of terconazole to treat uncomplicated vulvovaginal candidiasis.
Before taking terconazole, tell your health care provider:
Ask your health care provider about possible side effects from terconazole. Your health care provider will tell you what to do if you have side effects.
Take terconazole according to your health care provider’s instructions. Your health care provider will tell you how much terconazole to take and when to take it. Before you start terconazole and each time you get a refill, read any printed information that comes with your medicine.
More information about terconazole is available:
Last Reviewed: May 7, 2013
Last Updated: May 7, 2013